Navigation Links
New Drug, Other Trends To Double Smoking Cessation and Addiction Treatments

With the advent of a possible new blockbuster drug and greater reimbursement levels for the treatment of nicotine, alcohol, and drug addictions, global sales of smoking cessation and addiction treatments are expected to rise from revenues of little over $1.1 billion in 2005 to more than $2.3 billion in 2010, according to Smoking Cessation and Addiction Treatments: A World Market Analysis, a new study released today from Kalorama Information.

Nicotine is clearly the most abused drug worldwide, with over 1.4 billion incidences, including 50 million users in the U.S. alone. Smoking cessation has continually become a particular focus of global health agencies, and the increasing high awareness of effective smoking cessation products have helped to drive market growth.

The market now dominated by GlaxoSmithKline with its Zyban smoking cessation treatment, and Schering-Plough / Reckitt Benckiser with their Suboxone/Subetex substance abuse treatment, is primed for a dramatic change as Pfizer moves into smoking cessation.

"We believe Pfizer's Chantix will acquire the largest share of the market, overtaking GlaxoSmithKline in smoking cessation, and leading all addiction treatments based on the superior effectiveness of Pfizer's product in clinical studies," notes Melissa Elder, the report's author. "To a more limited extent, new drugs in alcohol and substance abuse treatments will also change those markets."

Smoking Cessation and Addiction Treatments: A World Market Analysis includes world incidence and data for nicotine addiction, drug addiction, and alcohol abuse; current and forecasted revenues through 2010; current and forecasted market share with consideration of new players in the market; reviews of current products and new products in the pipeline; and key trends driving pharmaceutical treatments for smoking cessation and drug/alcohol addiction.


'"/>




Page: 1

Related medicine news :

1. FDA Approves New HIV Drug, Viread
2. FDA Approves New Arthritis Drug, Bextra
3. New Drug, Pleconaril speeds recovery from common cold
4. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
5. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
6. Life-Saving Cancer Drug, Herceptin Will be Available Free for Breast Cancer Patients in Wales
7. Diabetes Drug, Exenatide, Good For Blood Sugar Levels and Weight Loss
8. FDA Gives Approval for Skin Cancer Drug, Zolinza
9. Was the Warning of a Severe Reaction To a Drug, Overlooked?
10. Anti-Craving Drug, Naltrexone Helps Women Quit Smoking
11. Teen Marijuana Use Does Not Predict Drug, Alcohol Abuse
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... compare student test score performance for the 2015-16 school year across Wisconsin’s public ... programs. Though it highlights important patterns in student test score performance, the report’s ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: